Explore this article's sources with AI
Follow PeptideMethods on Google
Tesamorelin metabolites persist in serum
A six-person administration study found tesamorelin metabolites in serum for up to two hours, while post-administration urine testing found none.
Why we wrote this. The study offers a direct human readout on specimen choice, while its six-person scale and short window require careful limits.
In this article (6 sections)
A six-person administration study found that urine testing missed tesamorelin even when the analytical limit of detection was far below the World Anti-Doping Agency performance threshold cited by the researchers. Serum testing performed better: metabolites were found in every volunteer for up to two hours after an injection, while intact tesamorelin appeared in only two people and only for up to 30 minutes[1]. The result supports a narrow laboratory conclusion, not a claim about clinical benefit or harm.
What the researchers tested
The study enrolled six healthy volunteers and followed 10 consecutive days of Egrifta injections. The authors described this as an administration study designed to test whether existing anti-doping methods could identify tesamorelin use. It was not a randomized efficacy trial, and it did not compare health outcomes between treatment groups[1].
Tesamorelin is a synthetic growth hormone-releasing factor analogue. The current US prescribing information limits Egrifta WR to reducing excess abdominal fat in adults with HIV and lipodystrophy. The label also says it is not indicated for weight-loss management[2]. That approved-use context is separate from the paper's anti-doping question and from the broader evidence summarized on our tesamorelin evidence page.
The team used solid-phase extraction followed by liquid chromatography and high-resolution tandem mass spectrometry. The reported limits of detection were 13 picograms per millilitre in urine and 41 picograms per millilitre in serum[1]. A lower analytical threshold means the method can register a smaller concentration, but it does not guarantee that a short-lived compound will remain present in the sampled material.
Why the analysis included metabolites
The researchers also incubated tesamorelin in fresh human serum to examine products created by proteolytic degradation. They identified five previously unreported metabolites. Oxidation at a methionine residue was observed in tesamorelin and its metabolites, so the analytical method added ions for sulfoxide and sulfone forms[1].
This laboratory step matters because an assay aimed only at the intact 44-amino-acid peptide can lose its target as the molecule breaks down. A metabolite can provide a different analytical target, although the abstract does not report a separate detection window for each of the five metabolites.
Urine produced no post-administration detections
The urine result was negative throughout the post-administration sampling described in the abstract. This remained true despite a reported detection limit 70 times lower than the WADA minimum required performance level and despite adding several metabolite targets[1]. The finding applies to this six-person protocol and this sample-analysis method. It does not show that every urine method will always fail under every exposure or collection schedule.
A negative analytical result is also not evidence that the medicine was absent from the body. It means the selected targets were not detected above the method's threshold in the sampled urine. Timing, specimen type, degradation, sample preparation, and instrument settings all shape that observation.
Serum gave a short metabolite window
In serum, at least one tesamorelin metabolite was found in all six volunteers for up to two hours after injection. Intact tesamorelin was detected in two of the six volunteers, with the latest reported detection at 30 minutes[1]. The contrast led the authors to recommend focusing analytical work on serum metabolites rather than intact tesamorelin in urine.
The phrase 'up to' is not a guaranteed window. The abstract does not provide person-by-person sampling times, concentrations, or variability for each metabolite, so it supports a maximum observed duration in this study rather than a universal timetable for detection.
What the small study can and cannot establish
The clearest strength is the direct post-administration design: the researchers knew tesamorelin had been given and could compare two specimen types against defined analytical targets. That distinction matters. The study also paired volunteer samples with an in-serum degradation experiment, which helped identify targets that intact-peptide testing could miss.
The main limitation is scale. Six healthy volunteers cannot define the full range of metabolism, clearance, or assay performance across age groups, health conditions, approved Egrifta users, or different laboratories. Ten consecutive administration days also represent one protocol. The abstract does not disclose enough detail to assess sex balance, collection density, or false-positive performance.
Nothing in this detection study changes the approved indication or resolves access rules. Readers looking for the US regulatory distinction between authorized medicine and other uses can consult our US tesamorelin regulation page. The paper answers a forensic-method question, not whether tesamorelin is appropriate for an individual.
What we do not yet know
Full interpretation requires details beyond the PubMed abstract: exact sampling intervals, measured concentrations, recovery and precision data, participant characteristics, and the validation results for each metabolite target. Independent replication would also be needed to show whether the serum strategy performs similarly across laboratories and instruments.
Future work could test larger and more diverse populations, compare alternative specimen types, and report sensitivity and specificity under blinded conditions. Until then, the defensible takeaway is limited: in this six-person study, serum metabolites outlasted intact tesamorelin, while the tested urine approach produced no post-administration detection.
**Medical disclaimer:** This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
How many people were in the tesamorelin detection study?
Six healthy volunteers received Egrifta injections over 10 consecutive days. This was an administration and analytical-method study, not a randomized efficacy trial.
Was tesamorelin detected in urine after administration?
No post-administration urine detection was reported with the tested method, even after several metabolite targets were added. That result is specific to this small study and method.
How long were tesamorelin metabolites detected in serum?
Metabolites were detected in all six volunteers for up to two hours after injection. Intact tesamorelin was detected in two volunteers for up to 30 minutes.
Does the study show whether tesamorelin is safe or effective?
No. The study evaluated analytical detection in urine and serum. It did not test clinical efficacy, long-term safety, or whether treatment is appropriate for an individual.
Sources
No revisions yet. First published .